The Omicron variant with a large number of spike gene mutations was designated as a Variant of Concern (VOC). The uncertainty associated with the infectivity, vaccine effectiveness, severity of infection, and other characteristics of the Omicron variant remains considerable. Preliminary evidence suggests that the risk of Omicron reinfection may increase. Creative Diagnostics has been tracking the latest genome data of the virus and has developed a series of recombinant SARS-CoV-2 mutant proteins to support the study of variants.

Mutations in the Spike Protein of Omicron:

• 30 changes (A67V, T95I, G142D, L212I, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F)
• Three deletions (Δ69-70, Δ143-145, Δ211)
• One insertion (ins214EPE)

Creative Diagnostics has launched Recombinant SARS-CoV-2 Omicron Variant (B.1.1.529) Protein for the research uses, such as Recombinant SARS-CoV-2 (COVID-19) Spike Protein NTD (B.1.1.529) [His] (DAG-WT549).

The SARS-CoV-2 spike protein NTD (B.1.1.529/Omicron) was expressed in HEK293 cells and fused a polyhistidine at the C-terminus. Mutants are A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE. 

For more detailed product list or more information about the Recombinant SARS-CoV-2 Omicron Variant (B.1.1.529) Protein, please feel free to contact us or visit our site: www.creative-diagnostics.com or send an inquiry by using the 'Request Information' option below.